MBRX vs. IMRX, OKYO, IKNA, CUE, PRLD, ATNM, CELU, STTK, HOWL, and RENB
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Immuneering (IMRX), OKYO Pharma (OKYO), Ikena Oncology (IKNA), Cue Biopharma (CUE), Prelude Therapeutics (PRLD), Actinium Pharmaceuticals (ATNM), Celularity (CELU), Shattuck Labs (STTK), Werewolf Therapeutics (HOWL), and Renovaro (RENB). These companies are all part of the "pharmaceutical products" industry.
Moleculin Biotech vs.
Moleculin Biotech (NASDAQ:MBRX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
Moleculin Biotech received 193 more outperform votes than Immuneering when rated by MarketBeat users. However, 70.37% of users gave Immuneering an outperform vote while only 49.36% of users gave Moleculin Biotech an outperform vote.
In the previous week, Moleculin Biotech had 6 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for Moleculin Biotech and 0 mentions for Immuneering. Moleculin Biotech's average media sentiment score of 0.60 beat Immuneering's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.
15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 1.9% of Moleculin Biotech shares are owned by company insiders. Comparatively, 25.0% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Moleculin Biotech presently has a consensus target price of $6.00, indicating a potential upside of 518.56%. Immuneering has a consensus target price of $15.33, indicating a potential upside of 936.04%. Given Immuneering's higher possible upside, analysts clearly believe Immuneering is more favorable than Moleculin Biotech.
Immuneering's return on equity of -79.19% beat Moleculin Biotech's return on equity.
Moleculin Biotech has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.22, indicating that its stock price is 122% less volatile than the S&P 500.
Moleculin Biotech has higher earnings, but lower revenue than Immuneering.
Summary
Immuneering beats Moleculin Biotech on 8 of the 14 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:MBRX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy MBRX Stock Free MBRX Stock Alerts